ARVINAS ALERT: Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Inc. On Behalf Of Arvinas Stockholders And Encourages Investors To Contact The Firm

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Arvinas, Inc. (“Arvinas” or the“Company”) (NASDAQ:ARVN) on behalf of Arvinas stockholders. Our investigation concerns whether Arvinas has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On May 1, 2025, Arvinas and its partner Pfizer announced that they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated two planned Phase 3 studies, following the termination of VERITAC-3 in January. According to The Fly, a financial news platform, Oppenheimer & Co.“was surprised by the announcement” and questioned whether“Arvinas' management isn't telling us the whole story.” Arvinas had repeatedly pointed to clinical progress for vepdegestrant and the drug's commercial opportunity, leaving investors caught off guard by the abrupt pivot. On this news, the price of Arvinas shares declined by $2.39 per share, or approximately 25%, from $9.62 per share on April 30, 2025, to close at $7.23 on May 1, 2025.

If you purchased or otherwise acquired Arvinas shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at ... , by telephone at (212) 355-4648, or by filling out this contact form . There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn , X , and Facebook , and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X .

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
...

MENAFN07052025004107003653ID1109521263